Unknown

Dataset Information

0

GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo.

ABSTRACT: Abnormallyactivated FGFR1 has been validated as a therapeutic target for differentcancers. Although a variety of FGFR inhibitors have shown benefit in manyclinical patients with FGFR1 aberration, FGFR1 mutant resistance such as V561Mmutation, has been reported. To date however, no FGFR inhibitors have beenapproved to treat patients with FGFR mutant resistance. Herein, we report that GZD824, athird generation ABL inhibitor (Phase II, China), overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo. GZD824potently suppresses FGFR1/2/3 with an IC50 value of 4.14 ± 0.96, 2.77 ± 0.082, and 8.10 ± 0.15 nmol/L. It effectively overcomes FGFR1-V561F/M and other mutantresistance in Ba/F3 stable cells (IC50 :8.1-55.0 nM), and effectively inhibits the growth of Ba/F3-FGFR1-V561F/M mutantxenograft tumors in vivo (TGI=73.4%, 49.8% at20mg/kg, p.o, q2d). GZD824may be considered to be an effective drug to treat patients with FGFR1 abnormalactivation or mutant resistance in clinical trials.

SUBMITTER: Jiang K 

PROVIDER: S-EPMC8290231 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo.

Jiang Kaili K   Tang Xia X   Guo Jing J   He Rui R   Chan Shingpan S   Song Xiaojuan X   Tu Zhengchao Z   Wang Yuting Y   Ren Xiaomei X   Ding Ke K   Zhang Zhang Z  

Cancer medicine 20210610 14

Abnormallyactivated FGFR1 has been validated as a therapeutic target for differentcancers. Although a variety of FGFR inhibitors have shown benefit in manyclinical patients with FGFR1 aberration, FGFR1 mutant resistance such as V561Mmutation, has been reported. To date however, no FGFR inhibitors have beenapproved to treat patients with FGFR mutant resistance. Herein, we report that GZD824, athird generation ABL inhibitor (Phase II, China), overcomes FGFR1-V561F/M mutant resistance in vitro and  ...[more]

Similar Datasets

Unknown YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFRL858R, T790M -mutant resistance in vitro and in vivo.
| S-EPMC5911580 | biostudies-literature
Unknown BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.
| S-EPMC6214101 | biostudies-literature
Unknown Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.
| S-EPMC5507680 | biostudies-literature
Unknown JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo.
| S-EPMC9570838 | biostudies-literature
Unknown CDK5 inhibition in vitro and in vivo induces cell death in myeloma and overcomes the obstacle of bortezomib resistance.
| S-EPMC7169959 | biostudies-literature
Unknown Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.
| S-EPMC3272303 | biostudies-literature
Unknown Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo.
| S-EPMC4546483 | biostudies-literature
Unknown Ginsenoside Rg5 overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter: <i>in vitro</i> and <i>in vivo</i> study.
| S-EPMC7031741 | biostudies-literature
Unknown GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo.
| S-EPMC7125355 | biostudies-literature
Unknown Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
| S-EPMC6742540 | biostudies-literature